简历显示：吴兴武先生:中国籍,理学硕士,持有中国证券投资基金业从业证书,曾任摩根士丹利华鑫基金 管理有限公司研究员,广发基金管理有限公司研究发展部、权益投资一部研究员、广发多元新兴股票型 证券投资基金基金经理(自2017年4月25日至2019年4月16日)、广发核心精选混合型证券投资基金基金经 理(自2015年2月17日至2020年2月10日)、广发鑫瑞混合型证券投资基金(LOF)基金经理(自2019年4月16 日至2020年7月29日)、广发再融资主题灵活配置混合型证券投资基金(LOF)基金经理(自2019年4月16日 至2020年7月31日)。现任广发轮动配置混合型证券投资基金基金经理(自2015年2月12日起任职)、广发医 疗保健股票型证券投资基金基金经理(自2018年10月16日起任职)、广发医药健康混合型证券投资基金基 金经理(自2020年10月21日起任职)、广发创新医疗两年持有期混合型证券投资基金基金经理(自2021年3 月19日起任职)。2022年11月4日起任广发竞争优势灵活配置混合型证券投资基金基金经理。曾任广发主 题领先灵活配置混合型证券投资基金基金经理。 来源：金融界 公开资料显示，广 ...

Core Viewpoint - The impact of the U.S. "reciprocal tariffs" on Chinese pharmaceutical companies is limited, with many companies reporting normal operations and minimal effects on their business [1][2][4][7][12]. Group 1: Company Responses - Heng Rui Pharmaceutical reported that overseas sales account for only 2.56% of its revenue, indicating that U.S. tariffs have a minimal impact on its business [1]. - Han Yu Pharmaceutical stated that it has a diversified market presence across North America, Asia, Europe, and South America, which mitigates risks from single market policy changes [2]. - Bai Yang Pharmaceutical noted that its supply chain is globally diversified, and the impact of tariffs is minimal [3]. - WuXi AppTec acknowledged that tariffs will have some impact but emphasized their optimized supply chain and management practices to minimize effects [4]. - Kangtai Biological confirmed that it has no products exported to the U.S. and is focusing on markets along the Belt and Road [5]. Group 2: Industry Trends - The medical device industry in China is rapidly developing, with companies like Mindray Medical actively seeking alternatives for U.S. imported raw materials [5]. - Companies are increasingly focusing on domestic production and local supply chains to counteract potential tariff impacts [6][8]. - The vaccine industry in China is evolving, with companies like CanSino Biologics transitioning from followers to leaders in vaccine technology [8][9]. - The overall sentiment among Chinese pharmaceutical companies is that the current tariff situation presents an opportunity for domestic substitution and innovation [10][12].

中欧医疗创新股票A股票持仓前十占比合计75.62%，分别为：药明合联（10.35%）、科伦博泰生 （10.15%）、药明生物（9.82%）、药明康德（9.60%）、康方生物（7.89%）、康龙化成（7.01%）、 恒瑞医药（6.20%）、凯莱英（5.87%）、百利天恒（4.70%）、泰格医药（4.03%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年3月31日，中欧医疗创新股 票A规模46.75亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日 ...

Market Overview - The Hong Kong stock market showed mixed performance with the Hang Seng Index rising by 0.7% to 22,662.71 points, while the Hang Seng Tech Index fell by 0.09% to 5,239.5 points, and the Hang Seng China Enterprises Index increased by 0.37% to 8,261.61 points [1] - Total trading volume reached 213.368 billion HKD [1] Blue Chip Performance - Nongfu Spring (09633) led blue-chip stocks with a 7.07% increase, closing at 38.6 HKD, contributing 8.44 points to the Hang Seng Index [2] - Other notable performers included Chow Tai Fook (01929) up 5.65%, Sands China (01928) up 5.35%, while CSPC Pharmaceutical (01093) fell by 5.96% [2] Sector Highlights - Major technology stocks had mixed results, with Meituan rising over 4% and Tencent and Alibaba increasing by over 1%, while Xiaomi dropped nearly 3% [3] - The gaming sector saw significant gains, with MGM China (02282) up 7.38% and Sands China (01928) up 5.35%, driven by increased tourist arrivals during the May Day holiday [3] - The airline sector also performed well, with China Eastern Airlines (00670) rising 7.3% and China Southern Airlines (01055) up 6.56% [4] Economic Indicators - The Macau gaming revenue for April reached 18.858 billion MOP, a year-on-year increase of 1.7%, with total revenue for the first four months at 76.514 billion MOP, up 0.8% [3] - The demand for air travel and rail travel saw double-digit growth during the May Day holiday, with civil aviation passenger numbers reaching a historical high of 2.19 million daily [5] Commodity and Resource Insights - Gold stocks rebounded, with Chifeng Jilong Gold Mining (06693) rising 12.86% as gold prices increased, surpassing 3,370 USD per ounce [6] - The rare earth sector experienced a surge, with prices for dysprosium and terbium rising significantly due to export restrictions [10] Notable Stock Movements - Shandong Molong (00568) saw a dramatic increase of 188.51% after being removed from risk warnings, closing at 5.02 HKD [8] - Yao Cai Securities (01428) rose 17.94% following a takeover bid from Ant Group [9] - Kinglong Magnet (06680) increased by 11.69% amid rising rare earth prices [10] Industry Developments - The pharmaceutical outsourcing industry may face short-term impacts from potential tariff measures announced by the U.S. government, but the long-term fundamentals remain stable [7] - China Software International (00354) gained 7.4% as the industry anticipates a shift towards the Harmony operating system due to changes in licensing agreements with Microsoft and Google [11]

Investment Rating - The investment rating for Pharmaron is Equal-weight [4] Core Insights - The industry view is considered Attractive, with a price target set at Rmb27.40, indicating a 3% upside from the current price of Rmb26.61 [4] - In 1Q25, Pharmaron reported revenue of Rmb3,099 million, reflecting a 16% year-over-year growth, aligning with the 2025 guidance of 10-15% growth [7] - The revenue streams from North America, EU, and China showed year-over-year growth of 16.8%, 26.6%, and 13.1%, respectively, contributing approximately 65%, 18%, and 15% to total revenue [2] - The customer base saw revenue from the top 20 pharmaceutical customers grow by 29% year-over-year, while other customers grew by 14% [2] - Adjusted non-IFRS net profit for 1Q25 was Rmb349 million, a 3.1% increase year-over-year, with softer growth attributed to depreciation and amortization costs from biologics capacity launch [7] Summary by Sections Financial Performance - 1Q25 revenue was Rmb3,099 million, up 16% year-over-year, consistent with the guidance for 2025 [7] - Net operating cash flow increased by 14.4% to Rmb853 million, with capital expenditures of Rmb556 million, up 11.4% year-over-year [2] Customer and Market Dynamics - Revenue from the top 20 pharma customers increased by 29% year-over-year, while other customers saw a 14% growth [2] - New order growth for both Lab services and CMC was over 10%, although it decelerated from over 20% in 2024 due to a higher order base in 1Q24 [7] Valuation Metrics - The company has a market capitalization of Rmb29,328.6 million and an enterprise value of Rmb33,234.4 million [4] - The projected EPS for the fiscal years ending in 2024, 2025, and 2026 are Rmb0.97, Rmb1.26, and Rmb1.00, respectively [4]

Market Overview - The Hang Seng Index rose 1.74% and the Hang Seng Tech Index increased by 3.08% on the first trading day of May [1] - Despite a seemingly positive outlook for US stocks, there was a significant outflow of $8.9 billion from the US stock market, marking the largest outflow since December 2023 [1] - The US Chamber of Commerce urged the Trump administration to implement a tariff exemption mechanism to prevent economic recession and harm to small businesses [1] Trade Relations - The Chinese Ministry of Commerce noted a shift in the US stance regarding tariff negotiations, indicating a willingness to engage in talks [2] - The FTSE China A50 index futures reacted positively, rising over 0.9%, and the offshore RMB appreciated significantly against the USD [2] - New tariff adjustments confirmed that auto parts from Canada and Mexico will be exempt from a 25% tariff starting May 3 [2] Automotive Sector - Xpeng Motors reported a record delivery of over 30,000 vehicles for six consecutive months, with specific models achieving significant sales milestones [3] - Leap Motor's delivery volume for April reached 41,039 units, a 173% year-on-year increase, leading to a stock price increase of over 7% [3] - Xiaomi's automotive division also saw a rise in deliveries, contributing to a stock increase of over 6% [3] Technology Sector - Major US tech companies like Meta, Microsoft, and Apple reported strong earnings, unaffected by tariff issues, and reaffirmed aggressive AI investment plans [4] - The upcoming US non-farm payroll report is anticipated to influence market expectations regarding Federal Reserve interest rate decisions [4] - President Trump's recent sanctions on countries purchasing oil from Iran are viewed as a bargaining chip rather than a definitive policy change [4] Berkshire Hathaway - Berkshire Hathaway's annual shareholder meeting is set to take place, where Warren Buffett will discuss market perspectives and investment strategies, including significant cash reserves [5] Nuclear Energy Development - There is a global surge in the development of small modular reactors (SMRs) driven by climate change initiatives and demand for clean energy [6] - China's advancements in SMR technology are notable, with significant projects like the BEST project aimed at demonstrating fusion energy generation [6] Company Performance - China State Construction International reported a 5.5% year-on-year revenue increase in Q1 2025, with a notable rise in technology-related income [7] - The company’s new contract value decreased by 29.1% year-on-year, but adjusted figures show a strong performance when excluding high baseline effects from previous major projects [8] - The technology segment's revenue contribution increased to 20%, indicating a positive trend in the company's business model and market positioning [8]

Market Overview - The Hong Kong stock market experienced a collective rise during the holiday, with the Hang Seng Index increasing by 1.74%, the Hang Seng China Enterprises Index rising by 1.92%, and the Hang Seng Tech Index climbing by 3.08% [1][2]. Technology Sector - Tech stocks saw significant gains, with Xiaomi Group rising over 6%, Alibaba and JD.com increasing by over 3%, and Tencent up by over 2% [2]. - Notable individual performances included Tencent Holdings at 487.80 HKD (+2.22%), Alibaba at 122.00 HKD (+3.83%), and Xiaomi at 53.10 HKD (+6.31%) [3]. Robotics and AI - Robotics stocks surged, with Horizon Robotics increasing by over 14%, and other companies like Shengye and Jinli Permanent Magnet rising by over 11% and 5%, respectively [4][5]. Healthcare and Biotech - The healthcare outsourcing sector was active, with Kanglong Chemical and WuXi AppTec both rising over 7%, and WuXi Biologics increasing by over 5% [6]. New Energy Vehicles - New energy vehicle companies saw substantial increases, with Leap Motor rising over 7%, Xiaopeng Motors and Xiaomi both up over 6%, and Li Auto and BYD increasing by over 3% [7]. Consumer Goods - Beer stocks performed well, with Hong Kong San Miguel rising over 4%, and Qingdao Beer and Budweiser APAC both increasing by over 2% [8]. - Home appliance stocks also strengthened, with Quan Feng Holdings rising over 7%, and Hisense and Techtronic Industries increasing by over 4% [9]. Gambling Sector - The gambling sector saw broad gains, with Galaxy Entertainment and MGM China both rising over 2% [10]. Restaurant Sector - The restaurant sector faced declines, with Yum China dropping over 7% and other companies like Chaogao and Cafe de Coral decreasing by over 1% [11]. Local Consumption - Local consumption stocks weakened, with Chao Yue Holdings falling over 6% and Chow Tai Fook down over 1% [13]. Stock Performance - Hong Kong Exchanges saw a peak increase of 3.46% during trading, reaching 352.6 HKD, marking a new high since early April [13]. - Standard Chartered Group's stock initially rose over 4% post-earnings but closed up only 0.71% at 113.6 HKD, with a total market value of 269.225 billion HKD [15]. Future Outlook - Huatai Securities noted that the market has largely priced in the impact of tariffs on earnings expectations, with a 1.5% downward adjustment in profit expectations for core offshore Chinese stocks [17].

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Views - The company's Q1 2025 revenue of 3.099 billion yuan represents a year-on-year growth of 16.03%, with a net profit attributable to shareholders of 306 million yuan, up 32.54% year-on-year [1][2]. - The report indicates that the company's revenue is in line with market expectations, and future performance is expected to show gradual quarter-on-quarter improvement [2]. - The company has adjusted its revenue forecasts for 2025-2027, with expected revenues of 14.077 billion yuan, 16.473 billion yuan, and 19.528 billion yuan, respectively [3]. Summary by Sections Financial Performance - In Q1 2025, the laboratory business generated 1.857 billion yuan in revenue, a 15.7% increase year-on-year, while the CMC business saw revenue of 693 million yuan, up 19.1% [2]. - The adjusted net profit for Q1 2025 was 349 million yuan, reflecting a 3.14% increase year-on-year [1][2]. - The gross margins for the laboratory and CMC businesses improved to 45.54% and 30.44%, respectively, with year-on-year increases of 140 basis points and 254 basis points [2]. Future Outlook - The company anticipates a continued upward trend in performance, supported by a rapid increase in new orders, which grew over 10% year-on-year in Q1 2025 [2]. - The company maintains its revenue guidance for 2025 at a growth rate of 10% to 15% [2]. Valuation and Earnings Forecast - The report adjusts the earnings per share (EPS) forecasts for 2025-2027 to 0.98 yuan, 1.22 yuan, and 1.54 yuan, respectively, with corresponding price-to-earnings (PE) ratios of 24, 19, and 15 times based on the closing price of 23.52 yuan per share on April 29, 2025 [3][8].

Investment Rating - The investment rating for the company is "Outperform" (maintained) [2] Core Insights - The company reported a strong recovery in Q1 2025, with revenue and profit both achieving double-digit growth. Q1 revenue reached 3.099 billion, a year-on-year increase of 16.03%, while net profit attributable to shareholders was 306 million, up 32.54% year-on-year [4][6] - All major business segments experienced growth, with laboratory services revenue at 1.857 billion (up 15.74% year-on-year) and a gross margin increase to 45.54%. CMC (small molecule CDMO) services revenue was 693 million (up 19.05% year-on-year) with a significant gross margin improvement to 30.44% [7] - The company is seeing strong growth from European clients, with revenue from North America and Europe increasing by 16.81% and 26.57% year-on-year, respectively. Revenue from global top 20 pharmaceutical companies grew by 29.05% year-on-year [7] - New orders are accelerating, with Q1 2025 new orders up over 10% year-on-year, and the company maintains its full-year guidance of 10%-15% revenue growth for 2025 [7] Financial Data and Profit Forecast - The company forecasts total revenue of 13.795 billion for 2025, with a year-on-year growth rate of 12.4%. The net profit attributable to shareholders is projected to be 1.819 billion, reflecting a growth rate of 1.4% [6][9] - The earnings per share (EPS) is expected to be 1.02 for 2025, with a gross margin forecasted to improve to 35.8% [6] - The return on equity (ROE) is projected to be 12.1% for 2025, with corresponding price-to-earnings (PE) ratios of 23, 20, and 17 for the years 2025, 2026, and 2027, respectively [6][7]

Investment Rating - The report maintains a "Strong Buy" investment rating for the company [3][7]. Core Views - The company has shown consistent growth in laboratory services over the past five quarters, with a significant increase in new orders, particularly in the CMC segment, indicating a positive outlook for revenue growth [7]. - The company expects a revenue growth of 10-15% for the full year 2025, supported by strong order trends and the gradual realization of CMC business [7]. - The financial projections for 2025-2027 indicate a steady increase in revenue and net profit, with expected revenues of 137 billion, 155 billion, and 179 billion respectively, and net profits of 19 billion, 22 billion, and 26 billion [7][10]. Financial Data and Valuation - For 2025, the company is projected to achieve total revenue of 137.46 billion, with a year-on-year growth of 12% [2]. - The adjusted net profit for 2025 is estimated at 18.56 billion, reflecting a 16% increase compared to the previous year [2][10]. - The earnings per share (EPS) for 2025 is projected to be 1.07, with a price-to-earnings (PE) ratio of 20.5 [2][11]. Revenue Breakdown - Laboratory services revenue for Q1 2025 reached 18.6 billion, showing a year-on-year growth of 15.7% [7]. - The CMC segment generated 6.9 billion in revenue for Q1 2025, with a year-on-year increase of 19.1% [7]. - Clinical research services reported revenue of 4.5 billion in Q1 2025, reflecting a year-on-year growth of 14.2% [7]. Shareholder Information - The total market capitalization of the company is approximately 41.4 billion, with a circulating market value of 33 billion [3]. - The major shareholder holds a 14.07% stake in the company [3]. Financial Ratios - The company’s return on equity (ROE) stands at 13.3%, with a debt-to-asset ratio of 39.8% [3][11]. - The projected net profit margin for 2025 is 13.8%, indicating a stable profitability outlook [11].